Compare MDGL & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDGL | BIO |
|---|---|---|
| Founded | 2011 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 8.0B |
| IPO Year | N/A | N/A |
| Metric | MDGL | BIO |
|---|---|---|
| Price | $495.90 | $300.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $597.54 | $358.50 |
| AVG Volume (30 Days) | ★ 330.7K | 209.5K |
| Earning Date | 02-25-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $740,640,000.00 | ★ $2,557,500,000.00 |
| Revenue This Year | $435.42 | $1.62 |
| Revenue Next Year | $54.59 | $2.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 864.21 | N/A |
| 52 Week Low | $265.00 | $211.43 |
| 52 Week High | $615.00 | $373.69 |
| Indicator | MDGL | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 39.49 |
| Support Level | $465.98 | $293.94 |
| Resistance Level | $502.36 | $316.63 |
| Average True Range (ATR) | 20.75 | 9.02 |
| MACD | -2.41 | -2.40 |
| Stochastic Oscillator | 30.57 | 16.71 |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.